Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Replants Combunox Sales Force For Pending Beta-Blocker Nebivolol

Executive Summary

Forest's plans to distinguish its marketed antihypertensive Benicar and the pending nebivolol include detailing the two products with separate sales forces

You may also be interested in...



Nebivolol Education Efforts Will Tout Performance In Hypertension Subgroups

Forest has already started conducting postmarketing studies for its antihypertensive nebivolol - in advance of the product's approval - "to further highlight potential differences from existing beta blockers," according to Investor Relations VP Charles Triano

Nebivolol Education Efforts Will Tout Performance In Hypertension Subgroups

Forest has already started conducting postmarketing studies for its antihypertensive nebivolol - in advance of the product's approval - "to further highlight potential differences from existing beta blockers," according to Investor Relations VP Charles Triano

Forest’s Namenda Combo Use Rises With Part D, Patent Expirations Loom

Forest is seeing a strong uptick in combination use of its Alzheimer's therapy Namenda (memantine) as a result of favorable Medicare Part D coverage

Related Content

UsernamePublicRestriction

Register

PS046783

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel